Understanding Hallucinations (Part I)

NCT ID: NCT01907568

Last Updated: 2016-10-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

700 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-06-30

Study Completion Date

2018-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Psychotic symptoms (hallucinations and delusions) are present in several psychiatric and neurological disorders as well as in the general population. Effective treatment strategies for these symptoms in all patients are lacking and treatment-response can presently not be predicted. To date, the exact pathophysiological mechanism of these symptoms remains unknown. By investigating (subtypes) of hallucinations and delusions in all populations, a common pathway may be found, leading to more effective treatment options. Alternatively, different subtypes may be associated with different pathophysiological mechanisms.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hallucinations No Hallucinations

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with schizophrenia

With and without hallucinations

No interventions assigned to this group

Patients with borderline personality disorder

With and without hallucinations

No interventions assigned to this group

Patients with hearing impairment

With and without hallucinations

No interventions assigned to this group

Patients with visual loss

With and without hallucinations

No interventions assigned to this group

Patients with Parkinson's Disease

With and without hallucinations

No interventions assigned to this group

Patients with Alzheimer's Disease

With and without hallucinations

No interventions assigned to this group

Patients with dementia with Lewy Bodies

With and without hallucinations

No interventions assigned to this group

Patients with Posttraumatic Stress Disorder

With and without hallucinations

No interventions assigned to this group

Patients with delirium

With and without hallucinations

No interventions assigned to this group

Healthy participants

With and without hallucinations

No interventions assigned to this group

Patients with mood disorder

With and without hallucinations

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age \> 18 years
* mentally competent
* in case of delirium: family member able to give informed consent
* Individuals with hallucinations will have to experience at least one episode of hallucinations over the last month.
* Individuals without hallucinations: no current hallucinations and a history of maximum 1 episode of hallucinations with a maximum duration of 1 week, at least two years ago.

Exclusion Criteria

* Age \<18)
* Participants that cannot read, speak or understand Dutch
* For all included diagnostic groups except delirium: Mentally incompetent individuals who are not capable to provide informed consent, as determined by their treating physician.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Medical Center Groningen

OTHER

Sponsor Role collaborator

Free University Medical Center

OTHER

Sponsor Role collaborator

Parnassia Groep

OTHER

Sponsor Role collaborator

UMC Utrecht

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Iris Sommer

Prof.Dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Iris Sommer, Prof, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

UMC Utrecht

Teus van Laar, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

UMC Groningen

Philip Scheltens, Prof, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Amsterdam UMC, location VUmc

Karin Slotema, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Parnassia Groep

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

VU Medical Center

Amsterdam, , Netherlands

Site Status RECRUITING

UMC Groningen

Groningen, , Netherlands

Site Status NOT_YET_RECRUITING

Parnassia Bavo Groep

The Hague, , Netherlands

Site Status RECRUITING

UMC Utrecht

Utrecht, , Netherlands

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mascha M.J. Linszen, MD

Role: CONTACT

Phone: +31887557468

Email: [email protected]

Sophie M. Heringa, PhD

Role: CONTACT

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mascha Linszen, MD

Role: primary

Odile van den Heuvel, MD, PhD

Role: backup

Anne-Marthe Meppelink, MD

Role: primary

Karin Slotema, MD, PhD

Role: primary

Mascha Linszen, MD

Role: primary

Sophie Heringa, PhD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NL42959.041.13

Identifier Type: OTHER

Identifier Source: secondary_id

UH-1

Identifier Type: -

Identifier Source: org_study_id